An Emory-linked abstract shown in Nashville found the link in past records. The authors say it isn't peer reviewed and patients shouldn't change medication over it.
Recap by typeshit. Full story at Medical Daily.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Covers the 28.3% versus 25.0% weight loss figures, the 12% who quit at 9 mg in TRIUMPH-2, and why online vials sold as Reta aren't the trial drug.
Across nearly 44,000 matched patients over 65, GLP-1 users had a 45% lower death risk, researchers report, though they also saw more osteoporosis and retinopathy.
Loading…